Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma

被引：0
作者：
Yu Tian
Haijuan Xiao
Yanhui Yang
Pingping Zhang
Jiahui Yuan
Wei Zhang
Lijie Chen
Yibao Fan
Jinze Zhang
Huan Cheng
Tingwei Deng
Lin Yang
Weiwei Wang
Guoyong Chen
Peiqin Wang
Peng Gong
Xing Niu
Xianbin Zhang
机构：
[1] Carson International Cancer Center,Department of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors
[2] Shenzhen University General Hospital,Department of Oncology
[3] Shenzhen University,Department of Trauma Surgery, The First Affiliated Hospital and College of Clinical Medicine
[4] Shaanxi Province,Department of Gastroenterology
[5] Affiliated Hospital of the Shaanxi University of Traditional Chinese Medicine,Department of Hepatobiliary Surgery
[6] Henan University of Science and Technology,Hepatobiliary Surgery
[7] Changhai Hospital,Department of Gastroenterology
[8] Naval Medical University,undefined
[9] China Medical University,undefined
[10] Shaanxi Province,undefined
[11] Xianyang Central Hospital,undefined
[12] People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital,undefined
[13] Changzheng Hospital,undefined
[14] Naval Medical University,undefined
来源：
Molecular Cancer | / 22卷
关键词：
Hepatocellular carcinoma; 5-methylcytosine; N; -methyladenosine; Therapeutic response; Pharmacogenomic landscape; Multi-omics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 368 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2021)Hepatocellular carcinoma Nat Rev Dis Primers 7 6-1314
[3]  
Siegel RL(2018)Hepatocellular carcinoma Lancet 391 1301-873
[4]  
Laversanne M(2022)Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma J Hepatol 76 862-1361
[5]  
Soerjomataram I(2022)Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma J Hepatol 76 1348-652
[6]  
Jemal A(2020)RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy Embo J 39 e103181-193
[7]  
Bray F(2019)Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma Hepatology 69 639-7250
[8]  
Llovet JM(2022)Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation Trends Genet 38 182-947
[9]  
Kelley RK(2019)Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA Theranostics 9 7239-1397.e1311
[10]  
Villanueva A(2021)HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation Signal Transduct Target Ther 6 76-315
12345678910